

IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in Scleromyxedema

Tania Petersen, Thibault Mahévas, Pauline Cannet, Jean-David Bouaziz, Camille Hua, Charles Zarnitsky, Philippe Modiano, François Lifermann, Bruno Sassolas, Olivier Carpentier, et al.

▶ To cite this version:

Tania Petersen, Thibault Mahévas, Pauline Cannet, Jean-David Bouaziz, Camille Hua, et al.. IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in Scleromyxedema. Clinical Laboratory, 2021, 67 (03), Online ahead of print. 10.7754/Clin.Lab.2020.200605. inserm-03175493

HAL Id: inserm-03175493 https://inserm.hal.science/inserm-03175493

Submitted on 20 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Short communication				
2					
3	IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal				
4	Immunoglobulins in Scleromyxedema				
5					
6	Tania Petersen ^{1,2} , Thibault Mahévas ³ , Pauline Cannet ^{1,2} , Jean-David Bouaziz ⁴ , Camille Hua ⁵ ,				
7	Charles Zarnitsky ⁶ , Philippe Modiano ⁷ , François Lifermann ⁸ , Bruno Sassolas ⁹ , Olivier				
8	Carpentier ¹⁰ , Arsène Mékinian ³ , Laurent Garderet ¹¹ , Pierre Aucouturier* ^{1,2} , Yannick				
9	Chantran* ^{1,2}				
10					
11	¹ Département d'Immunologie Biologique, Hôpital St-Antoine, Assistance Publique-Hôpitaux				
12	de Paris, France				
13	² Sorbonne Université / Inserm UMRS 938, Hôpital St-Antoine, Paris, France				
14	³ Service de Médecine Interne, Hôpital St-Antoine, Assistance Publique-Hôpitaux de Paris,				
15	France				
16	⁴ Service de Dermatologie, Hôpital Saint-Louis, Université de Paris, Assistance Publique-				
17	Hôpitaux de Paris, France				
18	⁵ Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris /				
19	Université Paris Est Créteil, EpiDermE (EA7379), Créteil, France				
20	⁶ Service de Rhumatologie, Groupe Hospitalier du Havre, Hôpital Jacques Monod, Le Havre,				
21	France				
22	⁷ Service de Dermatologie, Hôpital Saint Vincent de Paul, Université Catholique de Lille,				
23	Lille, France				
24	⁸ Service de Médecine Interne, Centre Hospitalier de Dax, Dax, France				
25	⁹ Département de Médecine Vasculaire, Médecine Interne et Pneumologie, Centre Hospitalier				
26	Universitaire (CHU) de Brest, Hôpital La Cavale Blanche, Brest, France				
27	¹⁰ Service de Médecine Interne, Centre Hospitalier Victor Provo, Roubaix, France				
28	¹¹ Service d'Hématologie Clinique, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux				
29	de Paris, France				
30					
31	* Equal contribution				
32					
33	Corresponding Author:				
34	Pierre Aucouturier				

35	UMRS 938, Kourilsky building					
36	184 rue du faubourg St-Antoine					
37	F-7012, Paris, France					
38	Tel: + 33 149 284 678					
39	Email: pierre.aucouturier@inserm.fr					
40						
41	Source of Funds: This work was supported by Assistance Publique – Hôpitaux de Paris (AP-					
42	HP) and Sorbonne Université (Paris, France)					
43						
44	Declaration of Interest: none					
45						
46	Running Title: Monoclonal IgG1 in scleromyxedema					
47						
48	SUMMARY					
49	Background: Scleromyxedema (SME) is a rare mucinosis associated with monoclonal					
50	gammopathy. Several biochemical peculiarities of monoclonal immunoglobulins (Ig) in SME					
51	patients were reported in case reports or short series, such as $IgG\lambda$ over-representation,					
52	cationic migration, and partial deletion.					
53	Methods: Monoclonal immunoglobulins (Ig) from the serum of 12 consecutive patients					
54	diagnosed with scleromyxedema (SME) were analyzed using electrophoretic and					
55	immunoblotting techniques.					
56	Results: All monoclonal Ig from 12 SME were of IgG1 subclass, with an overrepresentation					
57	of the lambda-type light chain and a cationic mobility on standard zone electrophoresis, as					
58	compared with 21 cases of monoclonal gammopathy of undetermined significance (MGUS)					
59	of IgG1 subclass. Reactivity with specific monoclonal antibodies demonstrated no evident					
60	deletion of the heavy chain constant domains, which was also confirmed by analysis of Ig					
61	heavy chain molecular weight on a purified monoclonal component from one case.					
62	Conclusions: Significant isotype restriction of both heavy and light chains, and peculiar					
63	biochemical properties suggest that monoclonal Ig might be involved in pathophysiological					
64	events of SME.					
65						
66	Keywords: scleromyxedema, monoclonal gammopathy, immunoglobulin, IgG subclass					
67						

Abbreviations: MGUS: monoclonal gammopathy of undetermined significance, SDS-PAGE:
 sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SME: scleromyxedema

- 70
- 71

INTRODUCTION

Scleromyxedema (SME) is a rare systemic mucinosis associated with a monoclonal 72 73 gammopathy (MG) that belongs to the recently described group of Monoclonal Gammopathy 74 of Cutaneous Significance (MGCS) [1]. It is characterized by a histological triad including intense dermal mucin deposition, increased fibroblast proliferation, and fibrosis, and is 75 76 responsible for a scleroderma-like syndrome associated with generalized papular eruption [2]. Various systemic manifestations are common in SME, including cutaneous, neurological, and 77 78 articular involvements. Dermato-neuro-syndrome (DNS), an acute encephalopathy leading to seizure, coma, and death, is the most severe complication of the disease. Despite the rare 79 80 association of SME with hematologic malignancy (10 - 15%) [3], mortality remains high 81 among reported SME cases [2,3].

The almost constant occurrence of MG in SME has made it a diagnostic criterion along with cutaneous eruption, the histological triad on skin biopsy, and the absence of a thyroid dysfunction [2,4]. However, a direct or indirect role of the monoclonal immunoglobulin (Ig) in SME pathogenesis remains uncertain. Treatments aimed at eradicating a monoclonal plasma cell proliferation proved efficient in certain cases [3,5,6].

Intrinsic biochemical peculiarities of monoclonal Ig in SME patients were reported. A cationic migration and IgG λ restriction was found in 5 cases [7]. In 1978, Kitamura et al. [8] found a low molecular weight (110 kDa) monoclonal IgG, suggesting deletion of a part of the Fd fragment, in a single case of SME. Subsequent studies showed that the monoclonal component is always of the IgG class with an over-representation of the lambda-type light chain [2,3].

Here, we identified the IgG subclass and light chain type of the monoclonal component in 12
SME cases, and assessed their biochemical peculiarities, including mobility on zone
electrophoresis and presence of constant domains of heavy-chains.

- 96
- 97

MATERIALS AND METHODS

98 **Patients**

99 Serum samples were collected from 12 consecutive patients diagnosed with SME, recruited 100 from 9 French centers between June 2017 and November 2018 by MINHEMON French 101 network (dysimmune disorders associated to hemopathies and cancers). Samples were kept at -20°C until analyses. As a control group for electrophoretic migration, 39 sera from
consecutive patients with MGUS were collected at the Saint Antoine hospital (Paris). All
analyses, including electrophoresis and immunochemical studies, were part of the routine
biological follow-up of patients.

106 Characterization of isotypes and electrophoretic mobility of serum monoclonal Ig

Serum monoclonal Ig were identified by standard immunofixation (Sebia, France).
Electrophoretic mobilities of monoclonal IgG were determined by measuring their retention
factor (Rf) relative to albumin. Then, relative mobilities of monoclonal IgG were normalized
against the Rf of a single serum IgG (SME patient #7) serving as an internal standard.

111 Characterization of IgG subclasses and presence of heavy chain constant domains

112 Monoclonal IgG subclass typing and reactivities for heavy chain constant domains CH1, CH2, and CH3 were performed using a home-made immunoblotting method [9]: appropriate 113 dilutions of serum samples were submitted to thin-layer agarose gel zone electrophoresis and 114 transferred by single pressure (15 g/cm² for 10 minutes) onto a 0.2 µm nitrocellulose 115 116 membrane. The membrane was then blocked for 30 minutes in 5% skimmed milk in phosphate buffered saline pH 7.4 (PBS) and cut into strips that were incubated for 60 minutes 117 118 at room temperature with appropriate primary mouse monoclonal antibodies diluted in 0.05% Tween-20, 0.02% bovine serum albumin PBS. The monoclonal antibodies were specific for 119 kappa and lambda light chains, and IgG1, IgG2, IgG3, and IgG4 heavy chain isotypes (clones 120 HP6053, HP6054, NL16, GOM2, ZG4, and RJ4, respectively) and for IgG constant domains 121 (anti-CH1: TM15, ZB8, HP6044; anti-CH2: G7C, HP6018; anti-CH3: X3A8, HP6017). After 122 washing with 0.05% tween-PBS at 4°C, strips of nitrocellulose membrane were incubated 123 with alkaline phosphatase-conjugated rabbit polyclonal anti-mouse IgG diluted in 0.05% 124 tween-20, 0.02% BSA/PBS. Strips were washed as before, and revealed by chromogenic 125 reaction with tetrazolium nitroblue / bromo-chloro-indolyl phosphate in 0.1 M NaCl 0.1 M 126 127 MgCl2 0.1 M TRIS/HCl buffer pH 9.5.

128 Purification of monoclonal Ig and heavy and light chain molecular weight determination

The monoclonal IgG could be purified from the serum of one SME case and from a control IgG1 myeloma patient, using ion exchange chromatography. Serum samples were fractionated on a diethylaminoethyl (DEAE)-Trisacryl column in 10 mM TRIS/HCl buffer pH 7.8 with a 0 to 0.1 M NaCl linear gradient. Protein fractions were concentrated by ultrafiltration and purity was assessed by standard thin layer agarose zone electrophoresis at pH 8.6. Purified (> 95%) fractions were reduced with 10 mM dithiothreitol in 1% sodium

- dodecyl sulfate (SDS) loading buffer at 95°C for 3 minutes, and 1 µg protein of each was
 fractionated by 12% SDS polyacrylamide gel electrophoresis (SDS-PAGE).
- 137 Statistical methods

138 Frequencies of monoclonal IgG1 and λ -type IgG were compared to those in a published series

of MGUS using Fisher's exact test. Electrophoretic mobilities were compared using Mann Whitney-Wilcoxon's test. Differences with a p value < 0.05 were considered significant.

- 141 Computations were performed using R software.
- 142
- 143

RESULTS

Patients were aged 29 - 75 years at the time of the study (mean: 61.2 ± 16.8 years) with a sex ratio of 1 (Table 1). Three patients presented with DNS and the remaining 9 had non-severe

146 forms of SME.

All 12 monoclonal Ig from the SME patients were of IgG1 subclass (Table 1 and Figure 1B), including 7 with a lambda and 5 with a kappa light chain. The IgG1 restriction was significant as compared with the occurrence of IgG1 in the largest published series of MGUS (155/241 (63%); p = 0.009) [10], while the predominance of lambda light chain isotype in SME (7/12,

151 58%) was not statistically significant as compared with the same series of MGUS (89/241, 37%) (p = 0.22).

In SME patients, the electrophoretic migration of the monoclonal component was significantly more cationic (median [IQR]: 1.00 [0.96 - 1.03]) than the 21 MGUS that displayed a monoclonal IgG1 (median [IQR]: 0.95 [0.85 - 0.98]; p = 0.03; Figure 1A).

Analyses of constant domain reactivity with a panel of CH1-, CH2- and CH3-specific monoclonal antibodies by immunoblotting led to conclude on the absence of any deletion of the heavy chain constant region in all 12 studied SME-associated monoclonal IgG1 (Figure 1B). This was confirmed by the SDS-PAGE analysis of one SME-associated monoclonal IgG1 kappa that we could purify, as it revealed normal sizes of both heavy and light chains (Figure 2).

162

163

DISCUSSION

164 This study demonstrates a strict IgG1 restriction of SME-associated monoclonal 165 immunoglobulins, and it confirms that most of them have a high isoelectric point as suggested 166 by their cationic migration on agarose zone electrophoresis.

167 The bias toward IgG class and lambda type light-chain in SME MG was already noted by 168 James et al. [7] but subclasses of IgG have not been analyzed, as far as we know. The actual importance of the IgG1 restriction in SME should be confirmed in a larger series, but italready appears quite significant in the present study.

The cationic electrophoretic migration of SME-associated monoclonal immunoglobulins has been evoked in small series or in a single case [7,8]. To our knowledge, this is the first statistical demonstration of cationic electrophoretic migration of SME monoclonal Ig as compared with classical MGUS. We found that this electrophoretic property is independent of the IgG1 restriction of SME-associated monoclonal component.

- On the other hand, we did not confirm the results from Kitamura et al. [8] suggesting a deletion of the Fd portion (most likely the CH1 domain) of a monoclonal IgG from one SME case. Indeed, all constant domains of the heavy chains were immunoreactive in our immunoblotting studies, while 1 to 3 distinct antibodies were tested for each domain. This was confirmed in one case whose monoclonal component could be purified and analyzed by SDS-PAGE, revealing normal sized heavy and light chains.
- The almost constant presence of a MG in SME, isotype restriction and basic nature of the 182 183 monoclonal component pinpoint the potential role of a monoclonal plasma-cell proliferation in the pathophysiology of SME. However, a direct pathogenic role of such hematologic event 184 185 and the bone marrow microenvironment remains unknown. The efficacy in severe cases of new treatments targeting putative plasma cell clones with concomitant hematological and 186 clinical response supports the hypothesis of a direct or indirect role of these cells in the SME 187 pathogenesis [3,5,6]. An old study has shown that serum factor(s), but not the monoclonal 188 immunoglobulin alone, could stimulate in vitro fibroblast proliferation [11,12]. A hypothesis 189 that has been suggested to explain this phenomenon could be the presence of an unknown 190 circulating cofactor that could stimulate proliferation in association with the monoclonal 191 immunoglobulin. Biochemical changes such as glycosylation and/or modifications of the 192 amino acid sequence of the immunoglobulin could affect its electric charge and explain the 193 194 strong association between cationic migration and SME. The great efficacy of high dose intravenous immunoglobulins in SME [2,3,13] could be 195 explained by their immunomodulatory functions, or by increased clearance of the monoclonal Ig or its complex 196 with a co-factor. Further studies, based for example on mass spectrometry analyses of the 197 198 serum secretome, as well as functional experiments using purified monoclonal Ig with and without other serum fractions on human in vitro fibroblast cultures, are required for better 199 understanding the implication of these peculiar monoclonal Ig in the pathophysiology of 200 SME. 201
- 202

203	Refere	ences
204	1.	Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant
205		concept. J Eur Acad Dermatol Venereol 2017 Jan;31(1):45-52. (PMID: 27501129)
206	2.	Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: A Multicenter Study of
207		Characteristics, Comorbidities, Course, and Therapy in 30 Patients. J Am Acad
208		Dermatol 2013 Jul;69(1):66-72. (PMID: 23453242)
209	3.	Mahévas T, Arnulf B, Bouaziz JD, et al. Plasma Cell-Directed Therapies in
210		Monoclonal Gammopathy- Associated Scleromyxedema. Blood 2020 Apr
211		2;135(14):1101-10. (PMID: 32027747)
212	4.	Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen
213		myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001 Feb;44(2):273-81.
214		(PMID: 11174386)
215	5.	Donato ML, Feasel AM, Weber DM, et al. Scleromyxedema: role of high-dose
216		melphalan with autologous stem cell transplantation. Blood 2006 Jan 15;107(2):463-6.
217		(PMID: 16179379)
218	6.	Cañueto J, Labrador J, Román C, et al. The combination of bortezomib and
219		dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare
220		disease with new clinical insights. Eur J Haematol 2012 May;88(5):450-4. (PMID:
221		22404151)
222	7.	James K, Fudenberg H, Epstein WL, Shuster J. Studies on a unique diagnostic serum
223		globulin in papular mucinosis (lichen myxedematosus), Clin Exp Immunol
224		1967;2:153-66. (PMID: 4166238)
225	8.	Kitamura W, Matsuoka Y, Miyagawa S, Sakamoto K. Immunochemical analysis of
226		the monoclonal paraprotein in scleromyxedema. J Invest Dermatol 1978
227		Jun;70(6):305-8. (PMID: 349088)
228	9.	Briault S, Courtois-Capella M, Duarte F, Aucouturier P, Preud'Homme JL. Isotypy of
229		serum monoclonal immunoglobulins in human immunodeficiency virus-infected
230		adults. Clin Exp Immunol 1988 Nov;74(2):182-4. (PMID: 3147151)
231	10.	. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-
232		term follow-up of 241 patients with monoclonal gammopathy of undetermined
233		significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004
234		Jul;79(7):859-66. (PMID: 15244381)
235	11.	. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast
236		proliferation. Science 1978;199(4328):545-7. (PMID: 622555)

- 237 12. Ferrarini M, Helfrich DJ, Walker ER, Medsger TA Jr, Whiteside TL.
- Scleromyxedema serum increases proliferation but not the glycosaminoglycan
 synthesis of dermal fibroblasts. J Rheumatol 1989;16(6):837-41. (PMID: 2778769)
- 240 13. Guarneri A, Cioni M, Rongioletti F. High-dose intravenous immunoglobulin therapy
- for scleromyxoedema: a prospective open-label clinical trial using an objective score
- of clinical evaluation system. J Eur Acad Dermatol Venereol 2017 31(7):1157-60.
- 243 (PMID: 28370513)
- 244

Table 1. Demographic, clinical, and biological characteristics of 12 patients withscleromyxedema

Patient	Gender/Age	Severity	Monoclonal Ig isotype	Electrophoretic mobility (normalized value)
1	H/60	Non severe	IgG1 λ	Medium/cathodic (0.98)
2	F/29	Severe, DNS, cardiomyopathy	IgG1 λ	Cathodic (1.00)
3	H/75	Non severe, cutis laxa- like eruption, MBL	IgG1 к	Cathodic (1.02)
4	H/73	Non severe	IgG1 λ	Cathodic (1.01)
5	F/71	Non severe	IgG1 λ	Cathodic (1.02)
6	F/29	Severe, DNS	IgG1 κ	Medium (0.92)
7	F/75	Non severe	IgG1 λ	Cathodic (1.00)
8	F/69	Non severe	IgG1 к	Cathodic (1.10)
9	M/51	Non severe	IgG1 λ	Medium (0.89)
10	M/53	Non severe	IgG1 к	Anodic (0.86)
11	M/55	Severe, recurrent DNS	IgG1 к	Cathodic (1.11)
12	F/75	Non severe	IgG1 λ	Cathodic (1.05)

247

248 DNS: dermato-neuro syndrome; Non severe disease: absence of DNS or mucinous
249 cardiomyopathy; MBL: monoclonal B lymphocytosis; Severe disease: presence of DNS or
250 mucinous cardiomyopathy

251

- 252 Figure legends
- 253

Figure 1. (A) Comparison of electrophoretic mobilities of serum monoclonal IgG from 12 patients with scleromyxedema (SME) and 21 subjects with IgG1 MGUS (*: p < 0.05). (B) Immunoblotting analysis of IgG subclasses, light chain type and antigenic reactivity of CH1, CH2 and CH3 domains of serum samples from 2 patients with SME (used antibody clones are mentioned below corresponding strips; SPE: serum protein electrophoresis).



259

Figure 2. Apparent molecular weight of purified monoclonal IgG1 kappa from patient #6, as compared with a purified myeloma IgG1 kappa. (A) Agarose zone electrophoresis showing serum and DEAE-purified fraction from patient #6. (B) 12% SDS-PAGE under reducing conditions of purified monoclonal IgG1 kappa from a scleromyxedema patient (SME #6) and a multiple myeloma IgG1 kappa (MM control), showing normal sized heavy chain (black arrow) and light chain (white arrow).

